Filtros de búsqueda

Lista de obras de Suzanne Trudel

A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells

artículo científico publicado en 2013

A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin.

artículo científico publicado en 2007

A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL)

artículo científico publicado en 2018

A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)

artículo científico publicado en 2018

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

artículo científico publicado en 2012

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma

artículo científico publicado en 2012

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial

artículo científico publicado en 2013

Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant

artículo científico publicado en 2015

Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience

scientific article published on 20 December 2018

Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant

artículo científico publicado en 2009

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

artículo científico publicado en 2011

An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo

artículo científico publicado en 2013

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma

artículo científico publicado en 2012

An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines

artículo científico publicado en 2020

Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules.

artículo científico publicado en 2011

Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

artículo científico publicado en 2019

Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapy

artículo científico publicado en 2012

Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution.

artículo científico publicado en 2013

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

scientific article published on 16 December 2019

CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice

artículo científico publicado en 2006

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

artículo científico publicado en 2004

Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents

scientific article published on 15 June 2013

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates

artículo científico publicado en 2017

Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance

artículo científico publicado en 2005

Conflicts of interest, authorship, and disclosures in industry-related scientific publications

artículo científico publicado en 2010

Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma.

artículo científico publicado en 2016

Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation ⬇️

artículo científico publicado el 3 de agosto de 2011

Cyproheptadine displays preclinical activity in myeloma and leukemia

artículo científico publicado en 2008

D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma

artículo científico publicado en 2013

Differential regulation of FGFR3 by PTPN1 and PTPN2.

artículo científico publicado en 2014

Effect of noncompetitive proteasome inhibition on bortezomib resistance

artículo científico publicado en 2010

Efficacy of thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2013

Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma

artículo científico publicado en 2010

Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain

artículo científico publicado en 2011

Identification of human plasma cells with a lamprey monoclonal antibody

artículo científico publicado en 2016

Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop.

artículo científico publicado en 2014

Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma

artículo científico publicado en 2005

Incorporating isatuximab in the treatment of multiple myeloma

artículo científico publicado en 2019

Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma.

artículo científico publicado en 2013

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

artículo científico publicado en 2004

Initial genome sequencing and analysis of multiple myeloma

artículo científico publicado en 2011

Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone

artículo científico publicado en 2014

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma

artículo científico publicado en 2013

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia

artículo científico publicado en 2014

Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.

artículo científico

Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy

scientific article published on 27 November 2019

Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia

artículo científico publicado en 2014

Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma

artículo científico publicado en 2014

MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma

artículo científico publicado en 2006

Measurement of protein phosphorylation stoichiometry by selected reaction monitoring mass spectrometry

artículo científico

Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134.

artículo científico publicado en 2011

Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.

artículo científico publicado en 2009

Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival.

artículo científico

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

artículo científico publicado en 2010

Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies

artículo científico publicado en 2014

Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance

artículo científico publicado en 2002

Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma

artículo científico publicado en 2008

Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma

artículo científico publicado en 2014

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma

scientific journal article

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma

artículo científico publicado en 2007

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma

artículo científico publicado en 2017

Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myeloma

artículo científico publicado en 2012

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom's macroglobulinemia

artículo científico publicado en 2017

Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival ⬇️

artículo científico publicado el 4 de noviembre de 2011

Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients

artículo científico publicado en 2016

Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

artículo científico publicado en 2010

Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation

artículo científico publicado en 2018

Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo.

artículo científico publicado en 2004

Spontaneous remission in a patient with t(4;14) translocation multiple myeloma

artículo científico publicado en 2009

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

artículo científico publicado en 2016

Tandem immunoprecipitation of phosphotyrosine-mass spectrometry (TIPY-MS) indicates C19ORF19 becomes tyrosine-phosphorylated and associated with activated epidermal growth factor receptor

artículo científico publicado en 2008

Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

artículo científico publicado en 2018

The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.

artículo científico publicado en 2007

The Tricyclic Antidepressant Amitriptyline Inhibits d-Cyclin Transactivation and Induces Myeloma Cell Apoptosis by Inhibiting Histone Deacetylases: In Vitro and In Silico Evidence ⬇️

artículo científico publicado el 10 de enero de 2011

The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells

artículo científico publicado en 2006

Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site

scientific article published on 29 April 2014

Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras

artículo científico publicado en 2019

Tyrosine phosphorylation of the Lyn Src homology 2 (SH2) domain modulates its binding affinity and specificity

artículo científico publicado en 2015

Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation

artículo científico publicado en 2005

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda